The impact of losartan on the lifetime incidence of ESRD and costs in Mexico

Armando Arredondo,* Thomas A. Burke,*** George W. Carides,** Edith Lemus,**** Julio Quero*****

* National Institute of Public Health, Cuernavaca, Mexico.
** Merck & Co., Inc., Blue Bell, PA, USA.
*** Merck & Co., Inc., Whitehouse Station, NJ, USA.
**** Outcomes Research, MSD Mexico.

ABSTRACT

Background. The RENAAL (Reduction of Endpoints in Type 2 Diabetes with the Angiotensin II Antagonist Losartan) study demonstrated that treatment with losartan reduced the risk of ESRD by 29% among hypertensive patients with type 2 diabetes and diabetic nephropathy. The objective of this study was to project the effect of losartan compared to placebo on the lifetime incidence of ESRD and associated costs from a third-party payer perspective in Mexico. Methods. A competing risks method was used to estimate lifetime incidence of ESRD, while accounting for the risk of death without ESRD. The cost associated with ESRD was estimated by combining the cumulative incidence of ESRD with the lifetime cost associated with ESRD. Total cost was estimated as the sum of the cost associated with ESRD from the three main public institutions in Mexico, the lifetime cost of losartan therapy, and other costs (non-ESRD/non-losartan) expected for patients with type 2 diabetes. Survival was estimated by weighting the life expectancies with and without ESRD by the cumulative risk of ESRD. Results. The projected lifetime incidence of ESRD for losartan patients was lower (66%) compared with placebo patients (83%). This reduction in ESRD resulted in a decrease in ESRD-related cost of M$49,737 per patient and a discounted gain of 0.697 life years per patient. After accounting for the cost of losartan and the additional cost associated with greater survival, we projected that treatment with losartan would result in a net savings of M$24,073 per patient. Conclusion. Treatment with losartan in patients with type 2 diabetes and nephropathy not only reduced the within-trial incidence of ESRD but is projected to result in lifetime reductions in ESRD, increased survival, and overall cost savings to public institutions in Mexico.
INTRODUCTION

Diabetes is considered to be the leading cause of end-stage renal disease (ESRD) in Mexico. There are an estimated 25,000 patients currently receiving chronic dialysis in Mexico, with the majority receiving continuous ambulatory peritoneal dialysis. While dialysis services are unrestricted in the private sector in Mexico, there are limitations to the use of dialysis services used by salaried workers in the formal economy (40% of population), and severe restrictions in the economically disadvantaged population using services from the Health Secretariat (45% of population). It is anticipated that the pressures for the use of dialysis services will continue to grow. The number of individuals receiving dialysis in Mexico is estimated to triple (to 75,000) by the year 2010, and the management of ESRD will continue to represent a challenge for the economically limited health institutions within Mexico. Healthcare programs aimed at preventing the onset of ESRD have the potential to substantially reduce the economic burden of ESRD in Mexico.

The RENAAL Study design and results have been reported in detail by Brenner et al. The RENAAL Study was a multinational, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the renoprotective effects of losartan in 1,513 patients with type 2 diabetes and nephropathy. Patients enrolled had type 2 diabetes and a urinary albumin: creatinine ratio of at least 300 mg/g on a first morning specimen and serum creatinine between 1.3 and 3.0 mg/dL. Ninety-seven percent of patients were either receiving antihypertensive therapy or were noted to have hypertension but were not receiving antihypertensive therapy at baseline. The RENAAL population was, on average, 60 years of age, 63% male, and 18% Hispanic. The study protocol was approved by the Institutional Review Board of each center, and all patients gave written informed consent. The primary efficacy endpoint was a composite of the time to first event of doubling of the serum creatinine concentration, ESRD, or death.

Statistical methods

• Cumulative Incidence of ESRD. We estimated the lifetime cumulative incidence of ESRD using a variation of the cumulative incidence competing risk method. This approach accounts for the possibility that a patient may die prior to requiring dialysis or transplantation. There are two components to this estimate. The first component is the hazard (risk) function for ESRD conditional on institutions in Mexico, namely those representing salaried workers in the formal economy (IMSS and ISSSTE), and the economically disadvantaged population which relies on services of the Ministry of Health.

RESEARCH DESIGN AND METHODS

Study design

The RENAAL Study design and results have been reported in detail by Brenner et al. In brief, RENAAL was a multinational, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the renoprotective effects of losartan in 1,513 patients with type 2 diabetes and nephropathy. Patients were randomized to losartan or placebo on a background of non-ACEI conventional antihypertensive therapy (e.g., diuretics, calcium-channel antagonists, alpha-or beta-blockers, centrally acting agents, or some combination of these types of medications). Patients enrolled had type 2 diabetes and a urinary albumin: creatinine ratio of at least 300 mg/g on a first morning specimen and serum creatinine between 1.3 and 3.0 mg/dL. Ninety-seven percent of patients were either receiving antihypertensive therapy or were noted to have hypertension but were not receiving antihypertensive therapy at baseline. The RENAAL population was, on average, 60 years of age, 63% male, and 18% Hispanic. The study protocol was approved by the Institutional Review Board of each center, and all patients gave written informed consent. The primary efficacy endpoint was a composite of the time to first event of doubling of serum creatinine, ESRD, or death.

Statistical methods

• Cumulative Incidence of ESRD. We estimated the lifetime cumulative incidence of ESRD using a variation of the cumulative incidence competing risk method. This approach accounts for the possibility that a patient may die prior to requiring dialysis or transplantation. There are two components to this estimate. The first component is the hazard (risk) function for ESRD conditional on
ESRD-free survival. This component measures the risk that a patient experiences ESRD at time t given that the patient has survived up to time t without ESRD. To determine the best estimate for this component we fit several parametric survival models to the RENAAL trial data on ESRD. These models included the Weibull, log-logistic, log-normal, and exponential. The Akaike Information Criterion (AIC) was used to determine the best fitting model. The AIC criterion is a commonly used measure of the goodness of model fit with smaller values indicating better fit than larger values. The AIC was lowest (best) for the Weibull model, which we therefore chose as our model for ESRD conditional on ESRD-free survival. However, because a diagnostic plot suggested non-proportional hazards, we fit completely separate Weibull models for losartan and placebo.

The second component to the cumulative incidence of ESRD is the ESRD-free survival function. This function measures the probability that a patient survives to time t without ESRD. To determine the best estimate for this component we again fit the same type of parametric survival models to the RENAAL trial data on ESRD and all-cause death. The AIC was lowest (best) for the Weibull model, which we therefore chose as our model for ESRD-free survival.

We then multiplied these two components (one) risk for ESRD conditional on ESRD-free survival, and (two) ESRD-free survival, and summed the products over time to obtain the lifetime cumulative incidence of ESRD.

Lifetime Survival. Life expectancy by treatment group was estimated by weighting the life expectancies with and without ESRD by the treatment specific lifetime probabilities of ESRD. Life years gained by preventing ESRD was estimated by taking the difference between life expectancy for patients without ESRD and life expectancy for patients with ESRD. These life expectancies were estimated with Weibull models applied to the RENAAL data.

ESRD-Related Costs. The lifetime mean cost associated with ESRD was estimated by multiplying the discounted (3%) cumulative incidence of ESRD by the discounted (3%) lifetime cost attributable to ESRD. ESRD costs consisted of the costs of dialysis obtained from the three most important public institutions in Mexico: the Ministry of Health or (Secretaria de Salud, SSA), the Mexican Social Security Institute (Instituto Mexicano del Seguro Social, IMSS), and the Institute for Social Security and Services for State Workers (Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, ISSSTE). The daily cost of dialysis at these institutions, weighted by the proportion using peritoneal vs. hemodialysis, was M$207, M$252, and M$223, at SSA, IMSS, and ISSSTE, respectively. The cost estimated included quantitative and qualitative differences between all inputs required to provide health care in each intervention. Before the estimation of average cost by intervention, unit costs were estimated using five categories: human resources – medical personal –, infrastructure, training for a patient relative, the average number of HD or PD, and general services. A single cost was then determined by taking an average of costs at the three institutions (M$227 per day). We applied the average daily cost to the life expectancy following dialysis, which we estimated based on survival data for diabetics started on dialysis in Mexico (forth years).

Table 1. Daily cost and use of dialysis by Mexican Public Institutions.

<table>
<thead>
<tr>
<th>Daily Cost (M$)</th>
<th>SSA*</th>
<th>IMSS**</th>
<th>ISSSTE***</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemodialysis</td>
<td>319.30</td>
<td>386.10</td>
<td>344.75</td>
</tr>
<tr>
<td>Peritoneal dialysis</td>
<td>189.94</td>
<td>207.01</td>
<td>322.67</td>
</tr>
<tr>
<td>Proportion of use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemodialysis</td>
<td>13%</td>
<td>25%</td>
<td>17%</td>
</tr>
<tr>
<td>Peritoneal dialysis</td>
<td>87%</td>
<td>75%</td>
<td>83%</td>
</tr>
<tr>
<td>Overall weighted cost (HD/PD, in M$)</td>
<td>206.76</td>
<td>251.78</td>
<td>222.56</td>
</tr>
</tbody>
</table>

* Ministry of Health; ** Mexican Institute for Social Security; *** Mexican Institute of Social Security for State Workers.
Total cost. Total cost was defined as the sum of the cost attributable to ESRD, the cost of losartan therapy, and additional costs expected for patients with type 2 diabetes but not related to ESRD treatment or study medication (M$18.54/day). The cost of losartan was estimated based on the price of losartan for public institutions, the overall within-trial usage of losartan by dose, and projected lifetime survival (see above). The 2004 price of losartan for public institutions in Mexico was M$11.59 for both the 50 mg and 100 mg tablets. We assumed that patients who discontinued study therapy incurred no additional medication costs. Given that there were no differences in the incidence of side effects between treatment groups, we assumed that the difference in the cost of side effects between treatment groups was zero. We also conservatively assumed that there were no differences in the cost of non-study medications between treatment groups as there was a small but not significantly greater use of non-study medications in the placebo group.

To estimate costs, we adopted the perspective of a healthcare system responsible for all direct medical costs. All randomized participants were included in the analysis on an intention-to-treat basis. The bootstrap method was used to construct 95% confidence intervals on treatment differences. All costs were discounted at an annual rate of 3% and are reported in 2004 Mexican pesos. The costs estimation was adjusted to the inflation applying an econometric adjustment factor to control inflation rates according to the 2004 prices index to the consumer in Mexico. It was also validated translating Mexican pesos to US dollars with June-2004 as a reference period.

Sensitivity analyses

We conducted several sensitivity analyses, including a 50% reduction in ESRD costs, confining losartan drug costs and ESRD reductions to the within-trial period, and accounting for all lifetime losartan drug costs while confining ESRD reductions to the within-trial period.

RESULTS

The projected cumulative incidence of ESRD beyond the RENAAL trial period is shown in table 2. Figure 1 shows these estimates coupled with the within-trial cumulative incidences reported in Gerth, et al. The addition of losartan therapy to the treatment regimens of persons with type 2 diabetes, hypertension, and nephropathy is estimated to result in a reduction in the lifetime cumulative incidence of ESRD from 83 to 66%. In turn we projected an absolute reduction in ESRD incidence of 16% (83-66%) and an NNT (number needed to treat) of 6 (1/0.16) to prevent one case of ESRD over a lifetime.

Table 3 summarizes the results for lifetime cost, cumulative incidence of ESRD, and life years saved. The majority of patients (71%) received the 100 mg per day dosage of losartan within the trial period. Lifetime losartan study medication cost was estimated to be M$20,275 per patient. In addition, losartan patients were projected to incur an additional M$5,388 of cost due to increased life expectancy. However, losartan reduced ESRD-related cost per patient by M$49,737 as compared with placebo due to a lower lifetime cumulative incidence of ESRD for losartan as compared with placebo. Thus, losartan treatment reduced total cost by M$24,073. We estimated that patients without ESRD would have a discounted (3%) life expectancy of 8.8 years whereas patients with ESRD would have a discounted life expectancy of 4.3 years. The difference, 4.4 years, is the expected life

Table 2. Projected beyond-trial cumulative incidence (percent) of ESRD.

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>Losartan</th>
<th>Placebo</th>
<th>Difference (losartan-placebo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 years</td>
<td>34.1</td>
<td>45.0</td>
<td>-10.9</td>
</tr>
<tr>
<td>10 years</td>
<td>60.4</td>
<td>77.6</td>
<td>-17.3</td>
</tr>
<tr>
<td>15 years</td>
<td>65.4</td>
<td>83.0</td>
<td>-17.6</td>
</tr>
<tr>
<td>20 years</td>
<td>65.8</td>
<td>83.3</td>
<td>-17.6</td>
</tr>
<tr>
<td>Lifetime</td>
<td>65.8</td>
<td>83.4</td>
<td>-17.6</td>
</tr>
<tr>
<td>(25 years)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
years gained by preventing ESRD. By taking the product of the discounted absolute risk reduction for ESRD, 0.157, and the discounted expected life years gained by preventing ESRD, 4.44 years, we obtain an estimate of 0.697 life years gained for losartan.

**Sensitivity analyses**

Table 4 shows the results of the sensitivity analyses. The cost of ESRD could be decreased by as much as 45% and losartan treatment would still be cost saving. A 50% reduction in ESRD costs would result in an added cost per patient of M$1125 and an incremental cost effectiveness ratio of M$1614. If we do not project additional reductions in ESRD incidence for losartan patients beyond the trial and account only for the losartan drug cost incurred within the trial, the net cost savings would be M$10,087. If we do not project additional reductions in ESRD incidence beyond the trial but include all beyond-trial losartan drug cost, the net cost savings would be 1447.

**DISCUSSION**

The results from this study suggest that the benefits observed during the RENAAL trial continue to grow during the beyond trial period. In particular, the lifetime projections indicate that the beyond-trial incidence of ESRD grows at a slower pace in the losartan + CT treated group as compared with the placebo + CT treated group. By delaying the need for dialysis, patients eventually die of other causes such as cardiovascular disease and thus never require renal replacement therapy.

This economic evaluation, which incorporates clinical, epidemiological and cost inputs, constitutes an evidenced-based approach to health policy and planning in the context of health care reform in middle income countries like Mexico. As the epidemiological transition further progresses from infectious to chronic or degenerative disease in Mexico, so will the health care demand for diseases such as diabetes, hypertension and ESRD and the need to identify effective disease prevention strategies. Gerth et al. recently estimated that there are 175,729 persons in Mexico with type 2 diabetes and nephropathy (urine albumin/creatinine > 300 mg/g).15 If the lifetime benefits of losartan were similar to those projected here from RENAAL, we might expect that lifetime losartan treatment would reduce the number of persons developing ESRD of their lifetime by 30,928. This reduction in ESRD would translate into an M$8,740 million (M$8.74 billion) reduction in the cost of ESRD and M$4,230 million (M$4.23 billion)

Table 3. Lifetime Cost (M$), Cumulative Incidence of ESRD, and Life Years Gained (3% discounting).

<table>
<thead>
<tr>
<th>Costs (M$)</th>
<th>Losartan</th>
<th>Placebo</th>
<th>Difference</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESRD related costs</td>
<td>181,795</td>
<td>231,532</td>
<td>-49,737</td>
<td>-97,324, -2,150</td>
</tr>
<tr>
<td>Study medication</td>
<td>20,275</td>
<td>0</td>
<td>20,275</td>
<td></td>
</tr>
<tr>
<td>Other costs (diabetes)</td>
<td>48,103</td>
<td>42,715</td>
<td>5,388</td>
<td>233, 10,543</td>
</tr>
<tr>
<td>Net costs</td>
<td>250,173</td>
<td>274,247</td>
<td>-24,073</td>
<td>-65,630, 17,483</td>
</tr>
<tr>
<td>Cumulative incidence of ESRD</td>
<td>0.573</td>
<td>0.729</td>
<td>-0.157</td>
<td>-0.306, -0.007</td>
</tr>
<tr>
<td>Life years gained by preventing ESRD</td>
<td>4.4</td>
<td>3.1, 5.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Life years gained by losartan due to ESRD prevention</td>
<td>0.697</td>
<td>0.033, 1.360</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4. Sensitivity analyses compared to base case (M$).

<table>
<thead>
<tr>
<th>Base Case</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Cost Savings</td>
<td>24,073</td>
<td>-1,125 (ICER = 1614)</td>
<td>10,087</td>
</tr>
<tr>
<td>Life years gained (3% discounted)</td>
<td>0.697</td>
<td>0.697</td>
<td>0.393</td>
</tr>
</tbody>
</table>
in net savings, based on the lifetime projection. These freed resources may be used to extend dialysis treatment to those who may not have otherwise qualified.

A potential limitation of this study is the use of the four years of within-trial data to project outcomes and costs beyond the trial. However, many medical interventions for chronic conditions have an impact on costs, and outcomes which extend over a patient’s lifetime. In these instances, a lifetime horizon may be the most appropriate time horizon for clinical and cost effectiveness. In addition, such a time horizon is required to quantify the implications of any differential mortality effect between alternative technologies.16

Another possible issue that may be raised is whether our model of ESRD incidence may have overestimated the reduction in the lifetime cumulative incidence of ESRD for losartan and thereby overestimated the reduction in cost. To address this issue, we conducted sensitivity analyses which accounted for the lifetime ESRD-related costs for patients experiencing ESRD within the trial, but did not project additional reductions in ESRD beyond the trial. Within the sensitivity analysis, it was observed that even in the absence of a continued beyond trial treatment benefit, the results show that losartan resulted in net cost savings.

It should be recognized that the ESRD incidence results from this evaluation are being applied to a setting, clinical practice in Mexico, which is quite different from the clinical trial setting of RENAAAL. The cumulative incidence of ESRD in clinical practice in Mexico may differ from that reported here; however, in the absence of epidemiological data from Mexico on the cumulative incidence of ESRD, it is difficult to predict the direction of this bias.

Finally, a trial similar to RENAAAL, comparing losartan plus conventional antihypertensive therapy (calcium-channel antagonists, diuretics, alpha-blockers, beta-blockers, and centrally acting agents) regimen to conventional antihypertensive therapy plus placebo regimen would no longer be ethical based on the conclusive benefit of losartan in terms of reducing the risk of doubling of serum creatinine, end stage renal disease, or death. The conducted of any randomized trial requires uncertainty by the trial investigators, and the scientific community as a whole, in terms of the relative benefits of the randomized therapies. However, given the paper’s focus on health economics this issue is beyond the present analysis.

In summary, in patients with type 2 diabetes, hypertension, and nephropathy, losartan is projected to reduce the cumulative incidence of ESRD, resulting in an NNT to prevent one case of ESRD of 6. This reduction in ESRD incidence is estimated to reduce the costs of ESRD by M$49,737 per patient and to increase life expectancy by 0.99 years (0.70 discounted). After accounting for the cost of losartan and the cost associated with greater survival, the reduction in ESRD would result in a net saving of M$24,073 per patient. Treatment with losartan in patients with type 2 diabetes, hypertension, and nephropathy can result in substantial lifetime reductions in ESRD and associated costs.

ACKNOWLEDGEMENT

This study was funded by Merck & Co., Inc.

REFERENCES

Correspondence and reprint request:

Dr. Armando Arredondo  
Instituto Nacional de Salud Pública